C000029812 Fees and Costs — Columbia Maryland Intermediate Municipal Bond Fund, Class A

Data updated: 2021-07-13

The net expense ratio is 0.82%: a 0.47% management fee, a 0.25% 12b-1 fee plus 0.24% other expenses, less a 0.15% fee waiver. This share class carries a maximum front-end sales load of 3.00% and a deferred sales charge of up to 0.75%. Portfolio turnover was 15%.

C000029812 Fees and Expenses

Annual operating expenses and sales charges of C000029812. Prospectus, as of August 31, 2020.

Annual operating expenses
Management fee0.47%
12b-1 fee0.25%
Other expenses0.24%
Gross expense ratio0.97%
Fee waiver−0.15%
Net expense ratio0.82%
Sales charges
Max front load3.00%
Max deferred load0.75%
Redemption fee—
Expense limitation in place (N-CEN)Yes
Fees waived or reduced during the yearYes
Waived fees subject to recoupmentNo

C000029812 Costs Over Time

On $10,000 invested in C000029812, assuming 5% a year before costs, total costs come to $882 over 5 years, cutting the return by 1.49% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).

$10,000 investedSell after 1 yearSell after 3 yearsSell after 5 years
Value before costs$10,500$11,576$12,763
Sales charges$376$300$300
Fund expenses (net expense ratio 0.82%)$84$261$454
Lost growth on money paid in costs$15$60$129
Total costs$474$621$882
Value after costs$10,026$10,955$11,881
Impact on return, per year4.74%1.91%1.49%

C000029812 Trading Costs

Brokerage costs reported on SEC Form N-CEN for the fiscal year ending April 30, 2021.

  • Explicit cost rate (commissions ÷ average net assets): —
  • Total broker commissions: —
  • Bought from dealers (principal trades, not a cost): $55.4M
  • Portfolio turnover (prospectus): 15%
  • Securities lending: none during the year

C000029812 Dealer Counterparties

Securities bought directly from dealers (principal trades).

BrokerAmountShare
RBC Capital Markets$10.5M25.28%
Barclays$5.4M13.02%
Citi$5.4M12.97%
Morgan Stanley$4.3M10.27%
Piper Jaffray & Co$3.6M8.54%
JPMorgan$3.4M8.09%
Goldman Sachs$2.7M6.49%
SumRidge Partners LLC$2.4M5.74%
UBS$2.0M4.83%
Mesirow Financial Inc$2.0M4.76%

For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.